1 | Barium | Barium 4件: Barium; Diagnostic test: barium esophagram; Procedure: speech and modified barium swallow study; Radiation: esophageal barium xray; | - |
- |
- |
019 2件: 19, 98 💬 |
2 | Beclomethasone dipropionate | Beclomethasone dipropionate 3件: Beclomethasone dipropionate; Combination product: beclomethasone dipropionate in addition to mc-evoo; Combination product: beclomethasone dipropionate in addition to refined oil; | 2件: D00689 D00689
D07495 D07495 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
085 3件: 85, 97, 98 💬 |
3 | Benralizumab | Benralizumab 3件: Benralizumab; Biological: benralizumab, biological: placebo to mepolizumab; Biological: mepolizumab, biological: placebo to benralizumab; | 1件: D09874 D09874 💬 |
1件: IL5RA 💬 |
Cytokine-cytokine receptor interaction 4件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
044 4件: 44, 45, 98, 162 💬 |
4 | Bethanechol | Bethanechol 1件: Bethanechol; | 1件: D01000 D01000 💬 |
5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 |
Alzheimer disease 13件: Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway |
098 1件: 98 💬 |
5 | Budesonide | 0.5 mg budesonide effervescent tablet for orodispersible use 49件: 0.5 mg budesonide effervescent tablet for orodispersible use; 1 mg budesonide effervescent tablet for orodispersible use; 1mg budesonide effervescent tablet for orodispersible use; 2mg budesonide effervescent tablet for orodispersible use; Budesonide; Budesonide ( zentacort capsules 3mg ); Budesonide (6 mg); Budesonide (9 mg); Budesonide 0.5mg orodispersible tablet twice daily; Budesonide 1mg orodispersible tablet twice daily; Budesonide 6 mg capsules, hard (bux-pvii prototype); Budesonide 6 mg prolonged-release capsule, hard (bux-pvii prototype); Budesonide 6 mg prolonged-release capsules, hard (bux-pvii prototype); Budesonide 9 mg capsules, hard (bux-pv); Budesonide 9 mg capsules, hard (bux-pvii prototype); Budesonide 9 mg prolonged-release capsule, hard (bux-pvii prototype); Budesonide 9 mg prolonged-release capsules, hard (bux-pvii prototype); Budesonide [0.4mg/ml] viscous suspension; Budesonide mmx; Budesonide mmx 6 mg tablet; Budesonide mmx®; Budesonide mmx® 6 mg; Budesonide mmx® 9 mg; Budesonide oral suspension; Budesonide oral suspension [0.2 mg/ml]; Budesonide plus prevacid; Budesonide-formoterol single inhaler; Budesonide-mmx; Budesonide-mmx®; Budesonide-mmx® 6 mg; Budesonide-mmx® 9 mg; Budesonide-mmx™; Budesonide/formoterol; Combination oral budesonide and rectal hydrocortisone; Formoterol/budesonide; High dose budesonide; High dose budesonide suspension; High dose budesonide tablet; High dose of budesonide; Inhaled/swallowed budesonide; Low dose budesonide; Low dose budesonide tablet; Methylprednisolone or budesonide; Oral budesonide; Oral budesonide suspension (mb-9); Oral budesonide suspension (obs); Oral viscous budesonide; Oral viscous budesonide (ovb); Viscous/swallowed budesonide; | 1件: D00246 D00246 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
066 9件: 66, 93, 94, 95, 96, 97, 98, 228, 299 💬 |
6 | Cow milk | - | - |
- |
- |
098 2件: 98, 210 💬 |
7 | Cromoglicic acid | - | 2件: D00526 D00526
D07753 D07753 💬 |
- |
- |
002 3件: 2 , 85, 98 💬 |
8 | Dexlansoprazole | Dexlansoprazole 1件: Dexlansoprazole; | 1件: D08903 D08903 💬 |
2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
098 1件: 98 💬 |
9 | Diphenylpyraline | - | 3件: D01172 D01172
D01627 D01627
D07862 D07862 💬 |
1件: HRH1 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
098 1件: 98 💬 |
10 | Dupilumab | Dupilumab 5件: Dupilumab; Dupilumab (blinded); Dupilumab (open-label); Dupilumab 300mg solution for injection; Dupilumab prefilled syringe; | 1件: D10354 D10354 💬 |
1件: IL4R 💬 |
Cytokine-cytokine receptor interaction 8件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Inflammatory bowel disease, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation |
051 4件: 51, 98, 160, 162 💬 |
11 | Esomeprazole | Esomeprazole 3件: Esomeprazole; Esomeprazole 20 mg; Nexium (esomeprazole magnesium); | 4件: D01984 D01984
D04056 D04056
D07917 D07917
D09339 D09339 💬 |
2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
013 6件: 13, 46, 86, 98, 298, 299 💬 |
12 | Famotidine | Famotidine 2件: Famotidine; Famotidine 20 mg; | 1件: D00318 D00318 💬 |
1件: HRH2 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction |
006 4件: 6 , 46, 86, 98 💬 |
13 | Fluticasone | Fluticasone 7件: Fluticasone; Fluticasone mdi; Fluticasone propionate; Fluticasone propionate, 800 mcg twice daily (post 4fed failure); Fluticasone propionate, 880 mcg twice daily (after 6fed failure); Fluticasone propionate, usp; Swallowed fluticasone; | 1件: D07981 D07981 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
098 3件: 98, 228, 299 💬 |
14 | Fluticasone propionate | Fluticasone propionate 4件: Fluticasone propionate; Fluticasone propionate, 800 mcg twice daily (post 4fed failure); Fluticasone propionate, 880 mcg twice daily (after 6fed failure); Fluticasone propionate, usp; | 1件: D01708 D01708 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
098 2件: 98, 228 💬 |
15 | Gold | Gold 7件: Gold; Gold nanocrystals; Mtx goldshield tablets; Other: comparator: cpet cycle ergometer (gold standard); Procedure: quantiferon-tb gold assay; Procedure: repair of cdh w/sis gold; Sodium aurothiomalate (intramuscular gold); | - |
- |
- |
002 38件: 2 , 5 , 6 , 13, 17, 34, 46, 49, 50, 53, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 158, 162, 171, 218, 222, 224, 227, 230, 271, 291, 294, 296, 298, 299, 310, 318 💬 |
16 | Honey | Device: manuka honey sinus rinse 3件: Device: manuka honey sinus rinse; Honey; Other: honey; | 1件: D06776 D06776 💬 |
- |
- |
057 3件: 57, 98, 299 💬 |
17 | Infliximab | 99m technetium infliximab 70件: 99m technetium infliximab; 99mtc-infliximab; Abp 710 - biosimilar to infliximab; Adalimumab and infliximab; Adalimumab, etanercept, golimumab or infliximab; Anti tnf therapy including infliximab; Anti-tnf: infliximab (infusion); Azathioprine or adalimumab and infliximab; Bdmard withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept); Biosimilar infliximab; Ct-p13 sc (infliximab); Cyclosporine vs infliximab; Inflectra (infliximab); Infliximab; Infliximab (bcd-055); Infliximab (ifx alone); Infliximab (ifx); Infliximab (inf) + mtx, db; Infliximab (remicade); Infliximab (remicade): 100 mg of lyophilized infliximab; Infliximab + methotrexate (mtx); Infliximab 10 mg/kg; Infliximab 20 mg/kg; Infliximab 3 mg/kg; Infliximab 5 mg/kg; Infliximab 5 mg/kg body weight infused over 2 hours; Infliximab 5 mg/kg every 6 weeks; Infliximab 7 mg/kg every 8 weeks; Infliximab [infliximab biosimilar 3]; Infliximab and adalimumab; Infliximab and azathioprine combination at week 0; Infliximab and azathioprine combination at week 14; Infliximab and mtx; Infliximab biosimilar; Infliximab control; Infliximab group; Infliximab increased dose; Infliximab increased frequency; Infliximab infusion; Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab; Infliximab with azathioprine (iifx + aza); Infliximab+azathioprine; Infliximab, adalimumab, certolizumab pegol; Infliximab, azathioprine; Infliximab, etanercept; Infliximab, etanercept, adalimumab; Infliximab, methylprednisolone, methotrexate; Infliximab-biosimilar; Infliximab-eu; Infliximab-innovator; Infliximab-pfizer; Innovator infliximab; Intravitreal infliximab; Methotrexate + infliximab; Other: infliximab (ifx) infusion; Other: measurement of drug (adalimumab/infliximab); Procedure: measurement of serum infliximab and anti-infliximab antibodies; Procedure: treatment according to current standards without knowledge of serum infliximab and anti-infliximab ab status; Remicade (infliximab); Remicade® (infliximab); Remicaide (infliximab); Remsima (infliximab); Response to infliximab associated with methotrexate; Sb2 (infliximab biosimilar); Sb2 (proposed biosimilar to infliximab); Ta-650 (infliximab); Tnf blockers (infliximab, adalimumab, etanercept); Topical infliximab; Trexan+salazopyrin+oxiklorin+prednisolone + infliximab; Tumor necrosis factor inhibitor (etanercept, infliximab, adalimumab, and golimumab); | 1件: D02598 D02598 💬 |
1件: TNF 💬 |
AGE-RAGE signaling pathway in diabetic complications 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway |
035 25件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 💬 |
18 | Lansoprazole | Dexlansoprazole 6件: Dexlansoprazole; Lansoprazole; Lansoprazole 30mg; Lansoprazole, amoxicillin, clarithromycin; Lansoprazole, clarithromycin, amoxycillin; Treat with lansoprazole 30 mg bid for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms; | 1件: D00355 D00355 💬 |
2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
063 7件: 63, 71, 85, 98, 166, 222, 299 💬 |
19 | Loratadine | Loratadine 1件: Loratadine; | 1件: D00364 D00364 💬 |
1件: HRH1 💬 |
Calcium signaling pathway 3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction |
013 3件: 13, 46, 98 💬 |
20 | Losartan | Lisinopril, losartan, and atorvastatin 12件: Lisinopril, losartan, and atorvastatin; Losartan; Losartan and atenolol or propranolol; Losartan and nebivolol; Losartan and other angiotensin receptor blockers; Losartan bluefish 50 mg; Losartan hexal; Losartan potasico; Losartan potassium; Losartan tablets & qingremoshen granule; Other: losartan; Sildenafil and losartan; | 2件: D00357 D00357
D08146 D08146 💬 |
1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
017 18件: 17, 19, 36, 46, 58, 66, 67, 85, 96, 97, 98, 113, 164, 167, 179, 215, 222, 299 💬 |
21 | Mepolizumab | Biological: benralizumab, biological: placebo to mepolizumab 7件: Biological: benralizumab, biological: placebo to mepolizumab; Biological: mepolizumab, biological: placebo to benralizumab; Mepolizumab; Mepolizumab (a-il-5 antibody); Mepolizumab 100 mg; Mepolizumab 300 mg; Sb-240563 (mepolizumab); | 1件: D04923 D04923 💬 |
1件: IL5 💬 |
Allograft rejection 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
044 4件: 44, 45, 98, 162 💬 |
22 | Methamidophos | - | - |
- |
- |
002 18件: 2 , 11, 13, 19, 46, 49, 58, 65, 70, 85, 86, 98, 113, 118, 129, 298, 299, 300 💬 |
23 | Mometasone | Mometasone 2件: Mometasone; Mometasone furoate; | 3件: D00690 D00690
D03325 D03325
D08227 D08227 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
098 2件: 98, 162 💬 |
24 | Mometasone furoate | Mometasone furoate 1件: Mometasone furoate; | 1件: D00690 D00690 💬 |
1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
098 2件: 98, 162 💬 |
25 | Montelukast | 5 mg montelukast 8件: 5 mg montelukast; Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Montelukast; Montelukast sodium; Montelukast teva; Montelukast, flurbiprofen, midazolam, digoxin, pravastatin and bms-986142; Montelukast/ singulair; Singulair (montelukast sodium); | 2件: D00529 D00529
D08229 D08229 💬 |
1件: CYSLTR1 💬 |
Calcium signaling pathway 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction |
013 5件: 13, 46, 85, 98, 228 💬 |
26 | Nitric Oxide | Inhaled nitric oxide 14件: Inhaled nitric oxide; Inhaled nitric oxide & inopulse delivery; Inhaled nitric oxide - 30 mcg/kg ibw/hr; Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr; Inhaled nitric oxide 75 mcg/kg ibw/hr; Nitric oxide; Nitric oxide 160 ppm; Nitric oxide for inhalation; Nitric oxide generated by the geno nitrosyl delivery system; Nitric oxide plus oxygen; Nitric oxide supplement; Other: oral nitric oxide testing; Procedure: exhaled nitric oxide; Procedure: exhaled nitric oxide assessment; | 1件: D00074 D00074 💬 |
- |
- |
046 8件: 46, 85, 86, 98, 210, 251, 294, 299 💬 |
27 | Omalizumab | Omalizumab 4件: Omalizumab; Omalizumab (xolair); Recombinant humanized monoclonal antibody omalizumab to ige; Rituximab combined with omalizumab; | 1件: D05251 D05251 💬 |
1件: FCER1A 💬 |
Asthma 4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway |
046 7件: 46, 53, 65, 98, 162, 226, 299 💬 |
28 | Omeprazole | Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin) 19件: Bms drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin); Clartihromycin, amoxicillin, and omeprazole; Diclofenac + omeprazole; Dimebon + omeprazole; Esomeprazole; Esomeprazole 20 mg; Naproxen 500 mg tablets (pn 200 minus omeprazole); Nexium (esomeprazole magnesium); Omeprazole; Omeprazole (uk licensed generic product); Omeprazole 20 mg; Omeprazole 20mg; Omeprazole 20mg bid; Omeprazole 40 mg; Omeprazole 40mg capsule; Omeprazole magnesium; Omeprazole rectally 1mg/kg; Pn 200 tablets (500 mg naproxen and 20 mg omeprazole); Rifaximin+omeprazole+miralax; | 4件: D00455 D00455
D01207 D01207
D05259 D05259
D05261 D05261 💬 |
2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
006 16件: 6 , 8 , 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299 💬 |
29 | Potassium | Dipotassium salt 5件: Dipotassium salt; Losartan potassium; Potassium; Potassium sparing diuretic; Potassium supplement; | 1件: D08403 D08403 💬 |
- |
- |
036 10件: 36, 46, 66, 67, 98, 115, 167, 179, 215, 235 💬 |
30 | Propofol | Device: propofol dosage 5件: Device: propofol dosage; Intubated with propofol (ip); Procedure: sedation with iv propofol; Propofol; Propofol-lipuro; | 1件: D00549 D00549 💬 |
16件: GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 |
GABAergic synapse 7件: GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction |
006 9件: 6 , 21, 22, 34, 46, 75, 84, 98, 296 💬 |
31 | Reslizumab | Reslizumab 1件: Reslizumab; | 1件: D08985 D08985 💬 |
1件: IL5 💬 |
Allograft rejection 13件: Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
044 2件: 44, 98 💬 |
32 | Sevoflurane | Intubated with sevoflurane (is) 3件: Intubated with sevoflurane (is); Sevoflurane; Sevoflurane anesthetics; | 1件: D00547 D00547 💬 |
- |
- |
006 6件: 6 , 21, 22, 34, 98, 296 💬 |
33 | Sirolimus | Rapamycin, sirolimus 22件: Rapamycin, sirolimus; Sirolimus; Sirolimus (formerly known as rapamycin); Sirolimus (study drug)+ace inhibitor + statin; Sirolimus 0,1% crème; Sirolimus 0.2%; Sirolimus 0.4%; Sirolimus 1mg/ml; Sirolimus 2 mg; Sirolimus 2%; Sirolimus and hydroxychloroquine 200 mg; Sirolimus and hydroxychloroquine 400 mg; Sirolimus ointment; Sirolimus oral liquid product 1mg/ml; Sirolimus oral product; Sirolimus, 2%; Skincerity plus sirolimus/rapamycin; Skinercity plus sirolimus/rapamycin; Tavt-18 (sirolimus); Temsirolimus; Temsirolimus tablets; Topical 0.1% sirolimus; | 1件: D00753 D00753 💬 |
1件: MTOR 💬 |
AMPK signaling pathway 50件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway |
002 40件: 2 , 6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬 |
34 | Sucralfate | Sucralfate 1件: Sucralfate; | 1件: D00446 D00446 💬 |
- |
- |
098 1件: 98 💬 |
35 | Technetium Tc-99m | - | - |
- |
- |
046 2件: 46, 98 💬 |
36 | Vitamin D | 10000iu vitamin d 36件: 10000iu vitamin d; 19 nor vitamin d; 25-hydroxyvitamin d3; 25oh-vitamin d; 5000iu vitamin d; Alendronate versus alfacalcidol (1-alpha oh vitamin d); Calcium and vitamin d combination; Cholecalciferol (vitamin d3); Cholecalciferol, vitamin d3; D6-25-hydroxyvitamin d3; Diagnostic test: vitamin d measurement; Ergocalciferol (vitamin d2); High-dose vitamin d (2000 iu per day); High-dose vitamin d3; Low dose arm receiving neutral oil and 400 iu/g of vitamin d every second day; Other: baseline serum vitamin d level at or above 50 nmol/l; Other: baseline serum vitamin d level below 50 nmol/l; Standard-dose vitamin d (400iu per day); Supplementation with vitamin d2/d3; Verum arm receiving vitamin d oil; Vitamin d; Vitamin d 100ug; Vitamin d 10ug; Vitamin d 25(oh)d; Vitamin d drops; Vitamin d in arm b; Vitamin d oil; Vitamin d powder; Vitamin d2; Vitamin d3; Vitamin d3 3000 ui daily; Vitamin d3 400 iu; Vitamin d3 4000 ui daily; Vitamin d3 6000 iu; Vitamin d3 800 ui/day then 800 ui/day; Vitamin d3: 3000 or 4000 ui/day then 2,000 ui/day; | - |
- |
- |
013 21件: 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 98, 179, 222, 228, 235, 274, 298, 299 💬 |
37 | Vonoprazan | Vonoprazan 1件: Vonoprazan; | 1件: D11784 D11784 💬 |
2件: ATP4A, ATP4B 💬 |
Collecting duct acid secretion 4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation |
063 2件: 63, 98 💬 |
38 | Wheat | Other: antigen (wheat base soy sauce) spray 3件: Other: antigen (wheat base soy sauce) spray; Other: wheat flour; Wheat; | 1件: D06902 D06902 💬 |
- |
- |
098 2件: 98, 266 💬 |
39 | Xanthan gum | Other: xanthan gum 2件: Other: xanthan gum; Xanthan gum; | 1件: D06333 D06333 💬 |
- |
- |
098 1件: 98 💬 |
40 | Xylose | Other: d-xylose 2件: Other: d-xylose; Xylose; | 1件: D06346 D06346 💬 |
- |
- |
098 1件: 98 💬 |